

**Supplementary Figure 1.** Evaluation of SARS-CoV-gene-specific qRT-PCR. (**a**) Violin plots showing Cq distributions of successive RNA dilutions of SARS-CoV-2 isolate FFM1 (MT358638). (**b**) Linearity of M-, Orf1- and S-gene qRT-PCRs. Amplification curves of the dilution series were used for the evaluation of S-and M-gene specific qRT-PCR. (**c**) Detection of SARS-CoV Frankfurt 1 (NC\_004718) and SARS-CoV-2 FFM1 (MT358638) strain RNA using M- and S-gene specific primer and probe pairs (Supplementary Table 3). (**d**) Comparison of Cq values obtained with S- or M-specific primes (*n* = 3). Error bars indicate standard deviation. RFU, relative fluorescence units; bp, base pairs; Cq, quantification cycle.



**Supplementary Figure 2:** Detection of SARS-CoV-2 RNA with M-gene-specific PCR primer and probe pairs using SYBR green. (a) Amplification curve of in vitro-transcribed RNA-standards and concentrated virus supernatants (d). (b and e) melt curve analysis and (c and f) melt peaks of M-gene amplicons. RFU, relative fluorescence units; bp, base pairs; Cq, quantification cycle.



**Supplementary Figure 3**. The sequence alignment of 4318 SARS-CoV-2 full-length genomes. Mapping of the genomes to the reference sequence was performed using the Geneious mapper program. Primer binding sites of RdRP- and M-gene primers (dark and light green arrows) and probes (red arrows) are indicated. Black bars show the number and position of mismatches found in 4318 full-length SARS-CoV-2 genomes on the reference sequence NC\_0445512. Graphical representation of the sequence conservation of nucleotide sequences is depicted as sequence logos. The relative sizes of the letters illustrate their frequency in the compared sequences. The heights of the letters are measures of the information content of the positions in bits.

Pool-Test Group	Patient No.	E Gene PCR	RdRp Gene PCR
	Pat.24	negative	negative
	Pat.25	negative	negative
	Pat.26	negative	negative
	Pat.27	negative	negative
	Pat.28	negative	negative
POOLI	Pat.29	negative	negative
	Pat.30	negative	negative
	Pat.31	negative	negative
	Pat.32	negative	negative
	Pat.33	negative	negative
	Pat.22	positive	negative
	Pat.18	negative	negative
	Pat.19	negative	negative
	Pat.23	positive	negative
	Pat.21	positive	negative
POOL2	Pat.34	negative	negative
	Pat.35	negative	negative
	Pat.36	negative	negative
	Pat.37	negative	negative
	Pat 38	negative	negative
	Pat 39	negative	negative
	Pat 17	negative	negative
	Pat 16	negative	negative
	Pat 40	negative	negative
	Pat 20	negative	negative
POOL3	Pat 41	positive	negative
	Pat 42	negative	negative
	I at.42 Pat 42	negative	negative
	I at.45 Pat 44	negative	negative
	I al.44 Dat 45	negative	negative
	Pat.45	negative	negative
	Pat.46	negative	negative
	Pat.47	negative	negative
	Pat.48	negative	negative
	Pat.49	negative	negative
POOL4	Pat.50	negative	negative
	Pat.51	negative	negative
	Pat.52	negative	negative
	Pat.53	negative	negative
	Pat.54	negative	negative
	Pat.55	negative	negative
	Pat.56	negative	negative
	Pat.57	negative	negative
	Pat.58	negative	negative
	Pat.59	negative	negative
TOOL3	Pat.60	negative	negative
	Pat.61	negative	negative
	Pat.62	negative	negative
	Pat 63	negative	negative

**Supplementary Table 1.** Compilation of patient samples used for the pool-testing with diagnostic-approved kits targeting SARS-CoV-2 genes E and RdRp.

Patient	Matarial	A a a / C a a d a a	Cluster of Infection	Compleme Compatibility	
No.	Material Age/Gender Cluster of Infection		Symptoms, Comorbiality		
Pat.1	Throat swab	44/f	Hubei, China	Dry cough, sore throat	
Pat.2	Throat swab	58/m	Hubei, China	Asymptomatic	
Pat.3	Throat swab	59/m	Israel	Rhinitis, cough, back ache	
Pat.4	Throat swab	52/f	Israel	Cough, pharyngitis, fever	
Pat.5	Throat swab	55/m	Israel	Cough	
Pat.6	Throat swab	64/m	Israel	Asymptomatic	
Pat.7	Throat swab	61/m	Israel	sore throat	
Pat.8	Throat swab	40/f	Israel	Mild pharyngitis	
Pat.9	Throat swab	54/f	Israel	Asymptomatic	
Pat.10	Nasopharyngeal swab	43/m	Unknown	Cough	
Pat.11	Stool	32/m	Italy	Cough, muscle ache, fever	
Pat.12	Nasopharyngeal swab	30/m	Italy, Austria	Diarrhea, sore throat, rhinitis	
Pat.13	Respiratory swab	37/f	Unknown	Cough, fever, muscle ache, fatigue	
Pat.14	Throat swab	27/m	Italy	Cough, rhinitis, headache, muscle ache, abdominal pain	
Pat.15	Respiratory swab	42/f	Germany	unknown	
Pat.16	Bronchoalveolar lavage	13/m	SARS-CoV-2 neg.	Non-Hodgkin Lymphoma, RSV- Pneumonia, ARDS	
Pat.17	Throat swab	5/m	SARS-CoV-2 neg.	SCT	
Pat.18	Throat swab	58/m	SARS-CoV-2 neg.	SCT	
Pat.19	Throat swab	70/m	SARS-CoV-2 neg.	Leukemia, SCT	
Pat.20	Throat swab	54/m	SARS-CoV-2 neg.	Fever, HIV(+)	
Pat.21	Throat swab	64/m	SARS-CoV-2 neg.	SCT	
Pat.22	Throat swab	76/m	SARS-CoV-2 neg.	SCT	
Pat.23	Throat swab	57/m	SARS-CoV-2 neg.	SCT	

**Supplementary Table 2.** Compilation of patient samples used for validation of M-gene PCR in a clinically relevant setting.

f: female; m: male; neg.: negative; SCT: stem cell transplantation; RSV: respiratory syncytial virus; ARDS: acute respiratory distress syndrome.

Oligo Name	Oligonucleotide Sequences (5'to 3')	Position within the SARS-CoV- 2 Genome	Length (nt)	Tm (°C)	%GC
SARS-CoV-2 Probe Orf1ab	6-Fam-ACGTCCAACTCAGTTTGCCT-BBQ1	303–322	20	50.0	59.8
SARS-CoV-2 Orf1ab-gene R	GTCTCCAAAGCCACGTACGA	364–345	20	55.0	60.0
SARS-CoV-2 Orf1ab-gene F	GATGGAGAGCCTTGTCCCTG	265–284	20	60.0	59.8
SARS-CoV-2 Probe-N	6-Fam-CGCATTGGCATGGAAGTCAC-BBQ1	29,228–29,247	20	55.0	60.2
SARS-CoV-2 N-gene R	TGTAGGTCAACCACGTTCCC	29,273–29,254	20	55.0	59.6
SARS-CoV-2 N-gene F	TGGCCGCAAATTGCACAATT	29,174–29,193	20	45.0	60.3
SARS-CoV-2 Probe E	6-Fam-TGCTTTCGTGGTATTCTTGCT-BBQ1	26,307–26,327	21	42.9	58.2
SARS-CoV-2 E-gene R	GCGCAGTAAGGATGGCTAGT	26,353–26,334	20	55.0	59.9
SARS-CoV-2 E-gene F	TTCGTTTCGGAAGAGACAGGT	26,254–26,274	21	47.6	59.3
SARS-CoV-2 Probe S	6-Fam-ACTTACTCCTACTTGGCGTGT-BHQ1	23,446–23,466	21	58.8	47.6
SARS-CoV-2 S-gene F	AAACAGCCTGCACGTGTTTG	23,492–23,511	20	60.2	50
SARS-CoV-2 S-gene R	GCACAGAAGTCCCTGTTGCT	23,412–23,431	20	60.5	55

Supplementary Table 3. Primers used for Supplementary Figure 1.

Gene	Primer/Probe	Position (nuc)	Mismatch	# Genomes with Mismatch	% Mismatch	Aligned CoV-2 Genomes
RdRP	Forward -	15,435	A>G	4	- 0.15	
		15,439	G>K	1		
		15,444	G>K	2		
		15,444	G>T	1		
	-	15,476	G>K	1	_	
	_	15,477	A>G	1		
	Probe	15,478	A>G	1	0.09	
		15,480	C>U	1		
		15,489	A>R	1		
	_	15,508	G>K	1	_	
	Reverse	15,509	C>Y	3	0.09	4318
		15,510	U>W	1		
		15,525	C>U	1		
		15,528	U>Y	1		
M	_	27,002	C>Y	1		
	Forward –	27,005	C>U	4	- 0.14	
		27,011	C>U	1		
		27,015	C>Y	1		
	Probe	27,033	G>K	4	0.43	
		27,046	C>U	16		
		27,046	C>Y	1		
	Reverse -	27,090	G>A	1		
		27,092	C>U	1	0.04	

**Supplementary Table 4.** Single nucleotide polymorphism positions and frequencies for RdRP- and M-gene primer/probe binding sites extracted from sequence alignment of over 4300 full-length SARS-CoV-2 genomes.

K: T or G; R: A or G; W: A or T; Y: C orT.